​
​

BioVie Stock (NASDAQ:BIVI)

OwnershipFinancialsChart
BioVie by TradingView

Previous Close

$3.51

52W Range

$1.04 - $58.20

50D Avg

$2.26

200D Avg

$4.71

Market Cap

$59.70M

Avg Vol (3M)

$5.57M

Beta

0.90

Div Yield

-

BIVI Company Profile

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

14

IPO Date

Sep 18, 2020

Website

BIVI Performance

BIVI Financial Summary

Jun 24Jun 23Jun 22
Revenue---
Operating Income$-32.18M$-45.08M$-27.25M
Net Income$-33.01M$-50.26M$-26.08M
EBITDA$-32.18M$-44.29M$-26.98M
Basic EPS$-7.30$-15.47$-10.58
Diluted EPS$-7.30$-15.50$-10.60

Fiscal year ends in Jun 24 | Currency in USD

Peer Comparison

TickerCompany
XFORX4 Pharmaceuticals, Inc.
MREOMereo BioPharma Group plc
DAWNDay One Biopharmaceuticals, Inc.
HOOKHOOKIPA Pharma Inc.
TERNTerns Pharmaceuticals, Inc.
INZYInozyme Pharma, Inc.
ELDNEledon Pharmaceuticals, Inc.
ABOSAcumen Pharmaceuticals, Inc.
AMLXAmylyx Pharmaceuticals, Inc.